Enzymatically regulated demineralisation of pathological bone using sodium hexametaphosphate

Area of Science:

• Biomaterials Science
• Orthopedic Research
• Pathology

Background:

• Pathological bone formation in soft tissues, such as heterotopic ossification, causes significant disability and affects prosthetic use.
• Recent high incidence in military amputees highlights the urgent need for effective treatments.
• Current treatments lack efficacy and control, necessitating novel therapeutic approaches.

Purpose of the Study:

• To investigate hexametaphosphate (HMP) as a demineralizing agent for pathological ossification.
• To explore the controlled activity of HMP by modifying local pH and alkaline phosphatase.
• To assess the specificity and efficacy of HMP in dissolving pathological bone mineral.

Main Methods:

• Micro computed tomography (micro-CT) to assess demineralization of pathological bone samples.
• In vitro inhibition of hydroxyapatite precipitation in supersaturated solutions.
• Mechanical testing (stiffness, force to failure, yield force) of rat tibiae treated with HMP.
• Micro X-ray fluorescence (micro-XRF) to analyze hydroxyapatite surface interactions.

Main Results:

• HMP demonstrated large-scale demineralization of pathological bone samples via micro-CT.
• HMP effectively inhibited hydroxyapatite precipitation in vitro.
• HMP significantly reduced stiffness and maximum force to failure in rat tibiae (49% and 41% reduction, respectively), without affecting yield force.
• Micro-XRF suggested HMP's demineralizing effect is solution-mediated, not surface-binding.

Conclusions:

• HMP is an effective demineralizing agent for pathological bone, specifically targeting hydroxyapatite.
• HMP's activity can be modulated by pH and alkaline phosphatase, offering potential for controlled therapeutic application.
• HMP presents a promising, specific therapeutic candidate for treating pathological ossifications with minimal impact on collagen.